Loading
companiesCompany
SynsoryBio
SynsoryBio builds protein drugs with built-in if-then logic: they stay switched off until they sense they are in diseased tissue, a way to make immune-activating and cell-killing biologics usable at doses that would otherwise harm healthy tissue. It is preclinical, with a small team and no recorded financing.
Overview
SynsoryBio is creating conditionally activated protein therapeutics that sense their location in the body and become active only at diseased tissue, a way to widen the therapeutic window of immune agonists and cytotoxic biologics whose toxicity to healthy tissue limits their dose in cancer and autoimmune disease. The approach is related to masked or protease-activated biologics. The company is tagged oncology in the YC directory and is preclinical with a very small team; no sourced financing rounds are recorded.
Headquarters
Boston, MA, US
Funding
All startupsStartupYC W24
Investors
Type
Stage
Startup · Y Combinator Winter 2024
Website
Similar pages
- CompanyGranza Bio
Shares Y Combinator, Cytokines & engineered cytokines and the tag yc.
- CompanyAluna
Shares Y Combinator and the tag yc.
- CompanyMednet (theMednet)
Shares Y Combinator and the tag yc.
- CompanyAlixia
Shares Y Combinator and the tag yc.
- CompanyVelorum Therapeutics
Shares Y Combinator and the tag yc.
- CompanyDelee
Shares Y Combinator and the tag yc.
- CompanyResistanceBio (Viosera Therapeutics)
Shares Y Combinator and the tag yc.
- CompanySerinus Biosciences
Shares Y Combinator and the tag yc.